News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Gilead (GILD) Can Spend Its $32 Billion Stockpile to Reignite Investor Optimism



1/11/2017 6:24:10 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Sliding hepatitis C treatment sales and discouraging news regarding its clinical-stage drug pipeline caused Gilead Sciences shares to tumble 29% in 2016. Can management rekindle investor optimism in 2017?

In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss what Gilead Sciences may do to get back on track, including how management could use its $31 billion cash stockpile to spark growth.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES